Member Info for Laura2022

Moving now

They raised £4.5mln at 2p 6 weeks ago

11:04

An insider has upper their stake yesterday

BELL raised £4.5mln very recently so no innedoate concern

China and Trump willing to talk ( seeBBC last hour)

Someone else taken 25% stake seemingly

They can get other suppliers

The UK government has said it will invest up to £600 million ($764 million) in the creation of a centralised health data platform, creating a single point of contact for medical researchers seeking to tap into NHS data.

Prime Minster Sir Keir Starmer said in a speech on the UK economy – in the wake of the introduction of US tariffs – that the new Health Data Research Service (HDRS) will make sure that patient data held within the NHS is "unlocked for the public good."

The centre will be located at the Wellcome Genome Campus in Cambridgeshire and the Wellcome Trust is providing around £100 million of the funding for its creation and operation.

While its primary function will be to serve as a gatekeeper for researchers seeking access to anonymised primary care and secondary care resources and mortality data, so project organisers don't have to sift through multiple sources, it will also support clinical research by matching patients to trials.

Starmer has also said clinical trials will be "fast-tracked" with the time it takes to get a trial set up cut to 150 days by March 2026, down from around 250 days in 2022, part of an effort to reverse a steady decline in commercial clinical trials in the UK in recent years.

"Through this new drive, patients will have improved access to new treatments and technologies," said Starmer. "We already saw the power of health data during the pandemic and this will allow the NHS to make huge strides in patient care."

Beijing says it's willing to communicate with US to resolve 'friction'

published at 09:02

09:02

We can bring you more reaction now from China, after it was with a 104% excess on some exports to the US.

The US will not solve problems like its trade deficit and "lack of industrial competitiveness" through the tariff measures, China says in a White Paper published today.

"They seriously damage global trade order and the security and stability of global industrial and supply chains," the document reads.

The paper sets out that China has "always" maintained China-US trade relations are "mutually beneficial".

An insider has upper their stake yesterday

BELL raised £4.5mln very recently so no innedoate concern

China and Trump willing to talk ( seeBBC last hour)

Someone else taken 25% stake seemingly

They can get other suppliers

Melon / Earl

Please look again

Melon

Already priced in in yesterday's RNS

Please.keep up

A posted called clenchedcheeks could be right yesterday

"Surely at this market cap a competitor or someone in the sector will make a bid? The IP alone has to be worth many times the current share price.

We were told that the orders were there"

Then today, unless corrected, we have just under 25% of the company bought

Jgunn went above 8% yesterday too

https://www.lse.co.uk/rns/BELL/holdings-in-company-5vmoz304c1u2vjf.html

23 paid here

BELL.will be NT to buy soon

Jungle

At £3mln cap thy just raised £5mln a month a go

No one owns 24% (90mln+)

Largest are 2 holders of about 8 and 10%

Major shareholders: Belluscura plc

NameEquities%Valuation

Elie Dangoor

10.02 % 

John Humphrey Gunn

7.827 % 

Nigel Wray

3.768 % 

David Poutney

3.552 % 

Tekcapital Plc

2.088 % 

Lombard Odier Asset Management (Europe) Ltd.

1.608 % 

Gresham House Asset Management Ltd. (Investment Management)

1.003 % 

Looking great

Off topic

Huge move BELL

Someone added more yesterday TR1 and someone just bought 25% of company

Has someone just bought 25% of BELL?

Is 25% of shares in issue ?

But largest holders wonky have 10%

9-Apr-2510:14:15

0.75

94,256,681

Even more impetus now with Trump pharma tariffs

Should benefitting IQAI as predominantly USA focused ?

Post-quarter end, on 1 April ‘25, Impax closed its acquisition of fixed-income specialist Sky Harbor Capital Management, increasing AUM by c. £1.1bn. This further boosts Impax’s fixed income business, which may prove advantageous given current market (and potentially economic) turmoil. Unsurprisingly, Impax has said that it now expects FY25 results to be below market expectations and our end-FY25 forecast AUM level falls c. 20% to £25.0bn. Running these changes through our DCF model results in a reduced fundamental value / share of 400p, down from 600p. But this valuation remains more than double the current share price which we believe does not reflect the underlying strength of the business.

Pharmaceutical companies are going to need even greater drug development efficiency now

Paladin

It's a strange day again across AIM and FTSE

Now 21/24